MEDAL- programmet var et prospektivt designet kardiovaskulært Safety Outcomes Program med poolede data fra tre randomiserede, dobbeltblindede aktive komparatorkontrollerede undersøgelser, MEDAL, EDGE II og EDGE.
Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Program The MEDAL Program was a prospectively designed Cardiovascular (CV) Safety Outcomes Program of pooled data from three randomized, double-blind active comparator controlled trials, the MEDAL study, EDGE II and EDGE.